Preliminary computational modeling of nitric oxide synthase 3 interactions with caveolin-1: influence of exon 7 Glu298Asp polymorphism
Mandar S. Joshi
Center for Cardiovascular Medicine, The Research Institute at Nationwide Children's Hospital, Columbus Ohio 43205, USA
Search for more papers by this authorCorresponding Author
John Anthony Bauer
Center for Cardiovascular Medicine, The Research Institute at Nationwide Children's Hospital, Columbus Ohio 43205, USA
*Corresponding author: Tel, 1-614-722-4984; Fax, 1-614-355-3444; E-mail, [email protected]Search for more papers by this authorMandar S. Joshi
Center for Cardiovascular Medicine, The Research Institute at Nationwide Children's Hospital, Columbus Ohio 43205, USA
Search for more papers by this authorCorresponding Author
John Anthony Bauer
Center for Cardiovascular Medicine, The Research Institute at Nationwide Children's Hospital, Columbus Ohio 43205, USA
*Corresponding author: Tel, 1-614-722-4984; Fax, 1-614-355-3444; E-mail, [email protected]Search for more papers by this authorAbstract
The significance of endothelial nitric oxide synthase 3 (NOS3) activity has been recognized for many years, however it was only recently that the complicated regulation of this constitutively expressed enzyme in endothelial cells was identified. A critical component of the NOS3 regulatory cycle in endothelial cells is its intracellular localization to caveolae. The caveolar coordination of NOS3, more specifically its interaction with caveolin-1 (Cav-1), plays a major role in normal endothelial NOS3 activity and vascular bioavailability of nitric oxide. We have recently shown that the presence of NOS3 exon 7 Glu298Asp polymorphism caused diminished shear-dependent NOS activation, was less extensively associated with caveolae, and had a decreased degree of interaction with Cav-1. Here, we carried out preliminary investigations to identify possible mechanisms of the genotype-dependent endothelial cell responses we observed in our previous investigations. Through this approach we tested the hypothesis that computer simulations could provide insights regarding the contribution of this single nucleotide polymorphism to regulation of the NOS3 isoform. We observed that in the Glu/Asp and Asp/Asp mutant genotypes, the amount of NOS3 associated with Cav-1 was significantly lower. Additionally, we have shown, using a theoretical computational model, that mutation of an amino acid at position 298 might affect the protein-protein interactions and localization of the NOS3 protein. These alterations might also affect the protein function and explain the enhanced disease risk associated with the presence of Glu298Asp polymorphism in the NOS3 protein.
References
- 1 Aird WC. Endothelium as an organ system. Crit Care Med 2004, 32: S271–279.
- 2 Andrews KL, Triggle CR, Ellis A. NO and the vasculature: Where does it come from and what does it do Heart Fail Rev 2002, 7: 423–445.
- 3 Angus JA. Role of the endothelium in the genesis of cardiovascular disease. Clin Exp Pharmacol Physiol 1996, 23: S16–S22.
- 4 Arnal JF, Dinh-Xuan AT, Pueyo M, Darblade B, Rami J. Endothelium-derived nitric oxide and vascular physiology and pathology. Cell Mol Life Sci 1999, 55: 1078–1087.
- 5 Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003, 101: 3765–3777.
- 6 Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 2003, 78: 869–881.
- 7 Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure: Impact on cardiovascular disease. Kidney Int Suppl 2003, 84: S50–53.
- 8 Andrews KL, Pannirselvam M, Anderson TJ, Jenkins AJ, Triggle CR, Hill MA. The vascular endothelium in diabetes: A practical target for drug treatment Expert Opin Ther Targets 2005, 9: 101–117.
- 9 Asahara T, Murohara T, Sullivan A, Silver M, Van Der Zee R, Li T, Witzenbichler B et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275: 964–967.
- 10 Lee PC, Kibbe MR, Schuchert MJ, Stolz DB, Watkins SC, Griffith BP, Billiar TR et al. Nitric oxide induces angiogenesis and upregulates αvβ3 integrin expression on endothelial cells. Microvasc Res 2000, 60: 269–280.
- 11 Lee PC, Salyapongse AN, Bragdon GA, Shears LL 2nd, Watkins SC, Edington HD, Billiar TR. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 1999, 277: H1600–H1608.
- 12 Van Hinsbergh VW. The endothelium: Vascular control of haemostasis. Eur J Obstet Gynecol Reprod Biol 2001, 95: 198–201.
- 13 Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001, 280: F193–F206.
- 14 Goligorsky MS, Li H, Brodsky S, Chen J. Relationships between caveolae and eNOS: Everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 2002, 283: F1–F10.
- 15 Garcia-Cardena G, Fan R, Stern DF, Liu J, Sessa WC. Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 1996, 271: 27237–27240.
- 16 Minshall RD, Sessa WC, Stan RV, Anderson RG, Malik AB. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 2003, 285: L1179–L1183.
- 17 Shaul PW, Anderson RG. Role of plasmalemmal caveolae in signal transduction. Am J Physiol 1998, 275: L843–851.
- 18 Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999, 19: 7289–7304.
- 19 Shah V, Toruner M, Haddad F, Cadelina G, Papapetropoulos A, Choo K, Sessa WC et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999, 117: 1222–1228.
- 20 Afrasyap L, Ozturk G. NO level and endothelial NO synthase gene polymorphism (Glu298Asp) in patients with coronary artery disease from the Turkish population. Acta Biochim Biophys Sin 2004, 36: 661–666.
- 21 Akcay A, Sezer S, Ozdemir FN, Arat Z, Atac FB, Verdi H, Colak T et al. Association of the genetic polymorphisms of the renin-angiotensin system and endothelial nitric oxide synthase with chronic renal transplant dysfunction. Transplantation 2004, 78: 892–898.
- 22 Benjafield AV, Morris BJ. Association analyses of endothelial nitric oxide synthase gene polymorphisms in essential hypertension. Am J Hypertens 2000, 13: 994–998.
- 23 Berdeli A, Sekuri C, Sirri Cam F, Ercan E, Sagcan A, Tengiz I, Eser E et al. Association between the eNOS (Glu298Asp) and the RAS genes polymorphisms and premature coronary artery disease in a Turkish population. Clin Chim Acta 2005, 351: 87–94.
- 24 Casas JP, Bautista LE, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23028 subjects. Circulation 2004, 109: 1359–1365.
- 25 Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, Biagini A et al. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003, 49: 389–395.
- 26 Fatini C, Sofi F, Gensini F, Sticchi E, Lari B, Pratesi G, Pulli R et al. Influence of eNOS gene polymorphisms on carotid atherosclerosis. Eur J Vasc Endovasc Surg 2004, 27: 540–544.
- 27 Gomma AH, Elrayess MA, Knight CJ, Hawe E, Fox KM, Humphries SE. The endothelial nitric oxide synthase (Glu298Asp and -786TC) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 2002, 23: 1955–1962.
- 28 Colombo MG, Andreassi MG, Paradossi U, Botto N, Manfredi S, Masetti S, Rossi G et al. Evidence for association of a common variant of the endothelial nitric oxide synthase gene (Glu298→Asp polymorphism) to the presence, extent, and severity of coronary artery disease. Heart 2002, 87: 525–528.
- 29 Chang K, Baek SH, Seung KB, Kim PJ, Ihm SH, Chae JS, Kim JH et al. The Glu298Asp polymorphism in the endothelial nitric oxide synthase gene is strongly associated with coronary spasm. Coron Artery Dis 2003, 14: 293–299.
- 30 Hibi K, Ishigami T, Tamura K, Mizushima S, Nyui N, Fujita T, Ochiai H et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998, 32: 521–526.
- 31 Hingorani AD, Liang CF, Fatibene J, Lyon A, Monteith S, Parsons A, Haydock S et al. A common variant of the endothelial nitric oxide synthase (Glu298→Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999, 100: 1515–1520.
- 32 Hingorani AD. Endothelial nitric oxide synthase polymorphisms and hypertension. Curr Hypertens Rep 2003, 5: 19–25.
- 33 Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998, 32: 3–8.
- 34 Markus HS, Ruigrok Y, Ali N, Powell JF. Endothelial nitric oxide synthase exon 7 polymorphism, ischemic cerebrovascular disease, and carotid atheroma. Stroke 1998, 29: 1908–1911.
- 35 Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the Glu298→Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001, 276: 26674–26679.
- 36 Joshi MS, Mineo C, Shaul PW, Bauer JA. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J 2007, 21: 2655–2663.
- 37 Guex N, Peitsch MC. SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling. Electrophoresis 1997, 18: 2714–2723.
- 38 Xu D, Xu Y, Uberbacher EC. Computational tools for protein modeling. Curr Protein Pept Sci 2000, 1: 1–21.
- 39 Corson MA, James NL, Latta SE, Nerem RM, Berk BC, Harrison DG. Phosphorylation of endothelial nitric oxide synthase in response to fluid shear stress. Circ Res 1996, 79: 984–991.
- 40 Fleming I, Busse R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol 2003, 284: R1–R12.
- 41 Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res 1999, 15, 43: 532–541.
- 42 Fulton D, Gratton JP, Sessa WC. Post-translational control of endothelial nitric oxide synthase: Why isn't calcium/calmodulin enough J Pharmacol Exp Ther 2001, 299: 818–824.
- 43 Schwede T, Kopp J, Guex N, Peitsch MC. SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Res 2003, 31: 3381–3385.
- 44 Kopp J, Schwede T. The SWISS-MODEL Repository of annotated three-dimensional protein structure homology models. Nucleic Acids Res 2004, 32: D230–D234.
- 45 Wand AJ. Dynamic activation of protein function: a view emerging from NMR spectroscopy. Nat Struct Biol 2001, 8: 926–931.
